Bacterial-fungal consortium denitrifies wastewater by 100%
A German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
NK cell therapy company NK:IO raises seed money
British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
Resistance blocker of immune checkpoint inhibitors gets patented
The EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Lilly presents impressing results for Alzheimer’s drug donanemab
Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Biomethane fuel offers negative carbon footprint
Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
Carbios raises €141m to boost enzymatic PET recycling
In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.
EG 427 expands Series A closing to €18m
Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.
Tasteful plant protein
Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
Seed money for unique topical hair growth inducer
Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.